Structural malformations of bone causing disproportionate short stature.
Achondroplasia: Most common skeletal dysplasia; caused by gain-of-function FGFR3 mutation.
Pathophysiology: Overactive MAPK signaling impairs chondrocyte proliferation and terminal differentiation.
Primordial Dwarfism:
Extreme, global pre- and postnatal growth failure with marked microcephaly and variable intellectual disability.
Etiology: Recessive genetic defects compromising fundamental cellular processes (mitotic spindle formation, DNA damage response).
Subtypes: Seckel syndrome (ATR gene), microcephalic osteodysplastic primordial dwarfism (MOPD) type II (PCNT gene), Meier-Gorlin syndrome.
Chromosomal Abnormalities:
Turner Syndrome (45,X): Universal short stature driven by haploinsufficiency of the SHOX gene.
Secondary Growth Impairment
Endocrine Deficiencies:
Growth Hormone Deficiency (Pituitary Dwarfism): Isolated or combined pituitary hormone deficiency. Features include severe postnatal growth failure, midface hypoplasia, high-pitched voice, delayed dentition, and truncal adiposity. Neonatal presentation includes hypoglycemia, prolonged conjugated jaundice, and micropenis.
Laron Dwarfism (Growth Hormone Insensitivity): Inability to respond to endogenous/exogenous GH. Characterized by severe short stature, frontal bossing, depressed nasal bridge, micropenis, elevated basal GH, and markedly low IGF-1 and IGFBP-3 levels. Usually caused by autosomal recessive GHR mutations.
Hypothyroidism: Deceleration of growth velocity. If unrecognized, causes severe, progressive growth failure and delayed bone age.
Cushing Syndrome (Glucocorticoid Excess): Characterized by acceleration in weight gain accompanied by simultaneous deceleration in linear growth. Glucocorticoids directly inhibit epiphyseal chondrocyte proliferation and suppress GH/IGF-1 production.
Nutritional and Systemic:
Malnutrition represents the most common global cause of poor growth.
Chronic kidney disease impairs growth via anorexia, GH insensitivity, and decreased IGF bioavailability.
Psychosocial Dwarfism:
Growth failure associated with emotional deprivation and disrupted parent-child attachment.
Manifests with delayed statural growth, bizarre eating behaviors (binging, eating from garbage), and reversible physiological suppression of GH secretion.
Idiopathic and Variants of Normal
Constitutional Delay of Growth and Puberty (CDGP):
Delayed tempo of maturation. Normal birth length, deceleration between 6 months and 2 years, followed by normal growth velocity along lower percentiles. Characterized by delayed bone age and delayed pubertal onset.
Idiopathic Short Stature (ISS):
Heterogeneous classification for postnatal short stature lacking identifiable systemic, endocrine, or nutritional etiology.
Systemic & Nutritional Disorders
Represents most common global etiology.
Initial weight deceleration; subsequent linear height impairment.
Consequence of severe emotional/parental deprivation.
Associated with transient, reversible GH secretory abnormalities.
Catch-up growth ensues upon placement in nurturing environment.
Diagnostic Evaluation
graph TD
A[Clinical Evaluation of Short Stature / Dwarfism] --> B{Assess Time Course}
B -->|Fetal Onset SGA/IUGR| C[Intrinsic Genetic Defects, Maternal, or Placental Factors]
B -->|Postnatal Onset| D{Assess Body Proportions}
D -->|Disproportionate| E[Skeletal Dysplasias or SHOX Deficiency]
D -->|Proportionate| F{Assess BMI & Weight Trajectory}
F -->|Decreasing BMI Weight Deceleration| G[Malnutrition or Chronic Systemic Disease]
F -->|Increasing or Preserved BMI| H[Endocrinopathy Workup]
F -->|Normal BMI / Specific History| I[Variants of Normal or Psychosocial Dwarfism]
G --> G1[Investigate: - Nutritional Deficits - Gastrointestinal e.g., Celiac, Crohn's - Renal Disease - Inflammatory e.g., JIA - Cardiopulmonary]
H --> H1[Check Thyroid Function: FT4, TSH]
H --> H2[Assess for Glucocorticoid Excess: Cushing Syndrome]
H --> H3[Screen for GH Deficiency: IGF-1 & IGFBP-3]
H3 --> H4{Are IGF-1/IGFBP-3 Low?}
H4 -->|Yes| H5[Provocative GH Testing x2]
H5 -->|Peak GH < 10 mcg/L| H6[Confirmed GH Deficiency Mandatory Brain MRI]
H4 -->|Normal but severe stunting| H7[Consider Laron Dwarfism GH Insensitivity]
I --> I1[Constitutional Delay CDGP: Delayed Bone Age & Puberty]
I --> I2[Idiopathic Short Stature ISS: Diagnosis of Exclusion]
I --> I3[Psychosocial Dwarfism: Emotional Deprivation History]
%% Specific mandatory note
E -.- J[Note: Karyotype mandatory in females with unexplained short stature for Turner Syndrome]
F -.- J
Clinical and Auxological Assessment
Time Course: Fetal onset (SGA/IUGR) suggests intrinsic genetic defects or maternal/placental factors. Postnatal onset suggests acquired systemic, endocrine, or nutritional pathology.
Body Proportions: Upper-to-lower segment ratio and sitting height index identify disproportionate short stature (indicative of skeletal dysplasias or SHOX deficiency).
Body Mass Index (BMI): Height deceleration with decreasing BMI indicates malnutrition or chronic disease. Height deceleration with increasing BMI indicates endocrinopathy (Cushing syndrome, Hypothyroidism, GH deficiency).
Laboratory and Imaging
Bone Age: Radiograph of left hand/wrist. Delayed in CDGP, malnutrition, and endocrinopathies.
Screening Labs: Complete blood count, comprehensive metabolic panel, celiac screen, thyroid function (FT4, TSH). Karyotype mandatory in females with unexplained short stature to rule out Turner syndrome.
IGF-1 and IGFBP-3: Screening biomarkers for GH deficiency. High overlap exists between normal variation and GH deficiency; low levels also seen in malnutrition and GH insensitivity.
Provocative GH Testing: Required for definitive diagnosis of GH deficiency because of pulsatile GH secretion. Peak GH < 10 mcg/L on two distinct pharmacological tests (insulin, arginine, clonidine, glucagon) supports diagnosis.
Neuroimaging: Brain MRI mandatory for confirmed GH deficiency to detect congenital malformations (septo-optic dysplasia) or acquired lesions (craniopharyngioma).
Management
Recombinant Human Growth Hormone (rhGH)
Indications: FDA-approved for GH deficiency, Turner syndrome, Prader-Willi syndrome, SGA without catch-up growth, Chronic Renal Insufficiency, Idiopathic Short Stature, SHOX haploinsufficiency, and Noonan syndrome.
Efficacy: Accelerates statural growth maximally during the first year of therapy. Normalizes adult height in classic GH deficiency.
Adverse Effects: Benign intracranial hypertension (pseudotumor cerebri), slipped capital femoral epiphysis (SCFE), progression of preexisting scoliosis, and transient insulin resistance.
Recombinant IGF-1 Therapy
Indications: Approved for severe primary IGF-1 deficiency (Laron dwarfism/GHR mutations, STAT5b mutations, neutralizing antibodies to GH).
Adverse Effects: High risk of severe hypoglycemia (up to 42% of patients); must be administered strictly alongside carbohydrate consumption. Other risks include lymphoid hypertrophy (tonsils/adenoids).